Dr. Tolaney on Remaining Questions With CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

Sara M. Tolaney, MD, MPH, associate director of the Susan F. Smith Center for Women’s Cancers; director of Clinical Trials, Breast Oncology; senior physician at Dana-Farber Cancer Institute, and assistant professor of medicine at Harvard Medical School, discusses remaining questions with CDK4/6 inhibitors in hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.